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Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity immune reaction
mediated by T-lymphocytes as a result of repeated exposure of an allergen primarily
on skin. ACD accounts for up to 95% of occupational skin diseases, with epoxy resins
implicated as one of the most common causes of ACD. Efficient high-throughput
in vitro screening for accurate identification of compounds and materials that may
pose hazardous risks in the workplace is crucial. At present, the murine local lymph
node assay is the ‘method of choice’ for predicting the sensitizing potency of contact
allergens. As the 3Rs principles of reduction, refinement, and replacement in animal
testing has gained political and economic momentum, several in vitro screening
methods have been developed for identifying potential contact allergens. To date, these
latter methods have been utilized primarily to assess the skin sensitizing potential of
the chemical components of cosmetic products with scant research attention as to the
applicability of these methods to industrial chemicals, particularly epoxy resins. Herein
we review the currently utilized in vitro methods and identify the knowledge gaps with
regard to assessing the generalizability of in vitro screening methods for assessing the
skin sensitizing potential of industrial chemicals.
Keywords: allergic contact dermatitis, epoxy resins, in vitro methods, skin sensitization, integrated hazard
classification
Introduction
Occupational skin diseases (OSDs) are a signiﬁcant public health concern both in terms of
employee pain and suﬀering as well as socioeconomic burden. In 2012 for the U.S. alone, the esti-
mated annual direct and indirect costs of OSDs exceeded USD1 billion per annum (Lushniak,
2004; Cashman et al., 2012). Additionally, the cost of dermatological treatments is forecast to
reach USD18.5 billion per annum by 2018 (Evers, 2013). These high socioeconomic costs have
provided the impetus for development of eﬃcient in vitro screening methods for accurately identi-
fying chemicals with high skin sensitization risk so that their industrial use can be avoided, thereby
reducing OSDs. One of the most commonly reported OSDs is contact dermatitis, which accounts
for up to 95% of occupation-related skin diseases (Lushniak, 2000) in the areas of medicine, beauty
products, manufacturing, and the construction industries (Gimenez-Arnau, 2011; Lowney and
Bourke, 2011; Sosted, 2011).
Contact dermatitis is an inﬂammatory skin reaction resulting from direct contact with
foreign substances, mainly aﬀecting exposed skin areas such as the hands, arms, legs, and
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face (Belsito, 2005). Contact dermatitis can be classiﬁed into irri-
tant contact dermatitis and allergic contact dermatitis (ACD).
In this review, we address (i) ACD and its associated contact
allergens, with particular attention on epoxy resins and their con-
stituents and (ii) in vitro methods that may be used for risk
assessment of ACD.
Allergic contact dermatitis is a type IV delayed hypersen-
sitivity cutaneous immune reaction that is mediated by T-
lymphocytes, and which occurs upon repeated skin exposure to
contact allergens (Kimber et al., 2002a). Brieﬂy, ACD develops
in two stages, the sensitization phase and the elicitation phase
(Figure 1; Toebak et al., 2009; Kimber et al., 2011). During the
sensitization phase, contact allergens/haptens initially come into
contact with the stratum corneum, the outermost layer of the
skin and subsequently gain access to the body system through
the viable epidermis. The invasion of haptens triggers the local
release of proinﬂammatory molecules which subsequently induce
the binding of haptens to skin proteins (Kimber et al., 2002a). The
release of proinﬂammatory molecules also stimulates the disen-
tanglement and subsequent migration of Langerhans cells (LCs)
from the surrounding keratinocytes toward the hapten–protein
complex (Schwarzenberger and Udey, 1996). The hapten–protein
complex binds to the major histocompatibility complex (MHC)
on LCs and is then transported into the lymph nodes via the
aﬀerent lymphatics (Toebak et al., 2009). During the transitory
migration to the lymph nodes, the activated LCs diﬀerentiate into
mature antigen presenting cells (APCs) resulting in morpholog-
ical changes such as the loss of endocytic/phagocytic receptors
and the upregulation of co-stimulatory molecules and MHC
molecules (Toebak et al., 2009). The hapten–protein complex is
presented by the APCs to the naïve hapten-responsive T-cells,
followed by selective clonal expansion of eﬀector and memory
T-cells. The proliferated population of primed antigen-speciﬁc
T-cells is then disseminated into the blood circulation result-
ing in the sensitization of an individual (Kimber et al., 2011).
Elicitation is triggered when the haptens interact with either the
same or a diﬀerent skin site (Kimber et al., 2011). Upon re-
exposure, epidermal cells release a cocktail of proinﬂammatory
cytokines and chemokines which draw the hapten-speciﬁc T-cells
from the peripheral circulation into the epidermal layer (Kimber
et al., 2011). The inﬁltrating T-cells produce pro-inﬂammatory
cytokines which in turn trigger the secretion of chemokines
by keratinocytes, resulting in increased inﬁltration of T-cells
from blood vessels into the epidermis leading to the devel-
opment of ACD (Basketter and Maxwell, 2007; Toebak et al.,
2009).
To date, more than 4000 chemical substances are linked to
induction of ACD in humans (Cahill et al., 2012). The 18-year
FIGURE 1 | Schematic overview of the mechanisms underpinning skin
sensitization during sensitization and elicitation phases: (1) Haptens gain
access through the viable epidermis. (2) Binding of haptens and skin proteins.
(3) Langerhans cells (LCs) bind to the hapten–protein complex and differentiate
into matured dendritic cells (DCs) during migration to the lymph node. (4) LCs
present haptenated protein to the naïve T-lymphocytes. (5) Clonal expansion of
specific effector and memory T-cells. (6) Proliferated T-lymphocytes disseminate
into the blood circulation resulting in sensitization of an individual.
(7) Re-exposure of similar haptens to the same individual. (8) Release of
proinflammatory cytokines and chemokines by epidermal cells. (9) Infiltration of
T-cells from blood vessels into the site of contact. (10) Development of allergic
contact dermatitis (ACD).
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retrospective analysis of ACD patients identiﬁed a number of
frequently deﬁned contact allergens, some of which have been
summarized in Table 1 (Cahill et al., 2012). These chemicals
have been compiled in several human patch tests series includ-
ing the North American Series, the European Baseline Series,
the International Standard Series and the Thin-layer Rapid Use
Epicutaneous Tests (TRUE). In brief, these series identify chemi-
cal substances commonly implicated in the population of a given
geographical area, to cause ACD (Spiewak, 2008).
Epoxy resin-induced ACD was ﬁrst reported in the 1950s, a
time when there was extensive development of epoxy resin sys-
tems (ERSs) in industry (Broughton, 1965). In general, an ERS is
comprised of an epoxy resin, hardener, reactive diluent, or other
additives such as solvents, modiﬁers and ﬁllers which together
control the chemical and physical properties of the ERS (Geraut
et al., 2009; Nixon et al., 2012).
Epoxy resin system components are the third most common
allergen types for occupational ACD after chromates and rubber
allergens, with ERS the primary source of ACD in the plastics
manufacturing industry (Geraut et al., 2009). The prevalence of
ERS-induced ACD by country is summarized in Table 2.
It was estimated that for individuals with ERS-associated
ACD, ∼60–80% were sensitized to diglycidyl ether bisphenol A
(DGEBA), an ERS that is widely used in industry (Björkner et al.,
2011). This high prevalence resulted in the inclusion of DGEBA
in the human patch test series since the 1960s (Geraut et al.,
2009). Other epoxy resins including diglycidyl ether bisphenol
F (DGEBF) and tetraglycidylmethylenedianiline, are also asso-
ciated with induction of ACD (Geraut et al., 2009; Nixon et al.,
2012).
Apart from epoxy resins, epoxy hardeners, predominantly
polyamine compounds such as triethylenetetramine (TETA) and
diethylenetriamine (DETA), as well as reactive epoxy diluents
TABLE 1 | Common allergens and sources of exposure.
Allergens Source
Epoxy resin system (ERS) Adhesives, paints
Formaldehyde Pesticides, home cleansers
Fragrance mix Toiletries, cosmetics
Neomycin sulfate Creams, deodorants
Nickel sulfate Costume jewelry, tools
(e.g., phenyl glycidyl ether and p-tert-butylphenyl glycidyl; Geier
et al., 2004), also cause ACD. A retrospective analysis of the
records of 182 patients with ACD induced by epoxy resins over
a 22-year period showed that 23.6% had developed an allergic
response to epoxy hardeners (Jolanki et al., 2001). In a prospec-
tive study involving 92 individuals with suspected and/or prior
exposure to ERS, patch tests showed that they were responsive to
the epoxy diluents, 1,6-hexanediol diglycidyl ether (19.5%), and
1,4-butanediol diglycidyl ether (18.5%; Geier et al., 2004), high-
lighting cross-reactivity between epoxy compounds for induction
of ACD in humans.
Although the high propensity of ERS to induce ACD is known,
they are nevertheless used widely in commercial thermoset-
ting products due to their strong adhesive bonding properties
between diﬀerent surfaces while exhibiting excellent resistance
in harsh chemical and environmental conditions (Cahill et al.,
2012). Worldwide demand for epoxy resins is forecast to reach
∼3 million tons by the end of 2017, with an estimated value
of USD9.2 billion per annum (GIA forecasts the global mar-
ket, 2012; Markets and Markets, 2014). The high global demand
for epoxy resins is due to their ever increasing utility in a wide
range of industrial applications including automotive coatings,
electronic coatings, construction and adhesive products (Dietrich
and Mirasol, 2012; GIA forecasts the global market, 2012). At
present, research on assessment of the generalizability of in vitro
tests developed for identifying the skin sensitizing potential of
small molecules used in the toiletries and cosmetics industries,
to that of epoxy resins and their components, is limited. Hence,
this knowledge gap needs to be addressed. Herein, we review
recent developments in non-animal tests for screening industrial
chemicals for skin sensitization potential, with particular atten-
tion to the applicability of these tests to the epoxy resin chemical
class.
Contact Allergens Screening
Approaches
Development of the ﬁrst animal models more than 80 years ago,
to substitute for human skin patch testing of chemical com-
pounds as potential contact allergens, was a landmark in terms
of minimizing if not altogether avoiding the need for human test-
ing (Landsteiner and Jacobs, 1935). About 40 years later, animal
TABLE 2 | Reported prevalence of occupational allergic contact dermatitis (ACD) due to epoxy resin systems (ERS).
Study period Country Study population
(number of individuals)
Prevalence of
ERS-induced ACD (%)
Reference
1993–2002 Australia 1354 3.0 Cahill et al. (2005)
1996–2006 North America 2540 0.9 Amado and Taylor (2008)
1997–2001 Norway 2336 1.0 Romyhr et al. (2006)
1999–2008 Portugal 2440 0.6 Canelas et al. (2010)
2001–2010 Denmark 219 8.2 Mose et al. (2012)
2001–2006 China 1354 8.5 Cheng et al. (2011)
2005–2009 Denmark 20 808 1.3 Bangsgaard et al. (2012)
2006–2008 Lithuania 816 1.5 Beliauskiene et al. (2011)
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models were introduced for assessing the sensitizing capacity of
ERS (Thorgeirsson and Fregert, 1977; Thorgeirsson, 1978; Gamer
et al., 2008; Ponten et al., 2009). At present, the murine local
lymph node assay (LLNA) is the ‘gold standard’ for assessing
the skin sensitization potential of contact allergens. However,
the use of animals for this type of testing has provoked much
ethical debate (Carlson et al., 2004; Basketter, 2009) and pro-
vided the impetus over the past decade for the development of
in vitro methods to replace, reduce, and reﬁne (3Rs) this type of
animal testing (Flecknell, 2002). Although several of these non-
animal testing methods are at the pre-validation stage, they have
been used primarily to assess the skin sensitization potential of
small molecules (molecular weights<500 Da) such as those used
in the manufacture of cosmetic and toiletry products (Kaplan
et al., 2012). However, their applicability for assessment of the
skin sensitization potential of ERS is largely unexplored. Hence
this knowledge gap needs to be addressed to enable the best
method or combination of methods to be identiﬁed for the reli-
able assessment of the skin sensitization potential of epoxy resin
compounds. In the following sections we review the current non-
animal testing approaches that have been developed based upon
key mechanistic events in the process of skin sensitization and
address the limitations of these methods for assessing the skin
sensitization potential of ERS.
In Chemico Assays: Peptide–Chemical
Interactions
Epoxy resins and/or epoxy resin composite materials, in com-
mon with other classes of haptens, react with skin proteins. The
hapten–protein complex is then internalized and processed by
LCs (Aleksic et al., 2007). Protein modiﬁcation, in a process
known as haptenation, is a key step in the initiation of skin sen-
sitization (Chipinda et al., 2011). Majority of contact allergens
are electrophilic in nature, consisting of Michael acceptors, SNAr
and SN2 electrophiles, Schiﬀ base formers, or acylating agents,
which underpin their ability to react with the nucleophilic amino
acid residues of skin proteins (Chipinda et al., 2011; Lalko et al.,
2012). For epoxy resins, the electrophilic epoxide groups react
with the nucleophilic moieties of skin proteins via SN1 or SN2
type nucleophilic reactions (Obach and Kalgutkar, 2010).
This haptenation process is mimicked in vitro by the direct
peptide reactivity assay (DPRA; Figure 2A) which assesses deple-
tion of small proteins (peptides) secondary to their interac-
tion with potential haptens (Gerberick et al., 2007). Brieﬂy, in
this model, synthetic peptides containing nucleophilic residues
including cysteine or lysine are incubated with test chemicals
at a pre-determined ratio for 24 h to allow the binding of the
active side chain of the peptide to the hapten. Based upon the
irreversible covalent bond formation that occurs between hap-
tens and amino acid residues in proteins, the DPRA quantiﬁes
the amount of unbound (remaining) peptide in the reaction mix-
ture using high performance liquid chromatography (HPLC).
Subsequently, the quantiﬁcation of the bound (depleted) pep-
tides is determined as a measure of reactivity of the test chemical
(Gerberick et al., 2004).
At present, the DPRA has been validated by the European
Centre for the Validation of Alternative Methods (ECVAMs)
for the assessment of contact allergens as a replacement for the
in vivo LLNA (Troutman et al., 2011). A test guideline has been
promulgated by the Organization for Economic Co-operation
and Development (OECD) highlighting the generalizability of
peptide reactivity with small molecules (OECD, 2015). However,
the suitability of the DPRA test system for chemicals such
as epoxy resins that contain an epoxide group remains to be
assessed.
DPRA: Chemicals Tested to Date
Use of the DPRA to assess the ability of 82 compounds that
are mainly used as ingredients in cosmetic and toiletry prod-
ucts, to deplete cysteine-, lysine-, and glutathione-based peptides,
indicated a signiﬁcant correlation between peptide depletion and
their sensitizer potency as previously established from in vivo
LLNA data (Gerberick et al., 2007).
Steps undertaken to improve the accuracy of the DPRA
for identiﬁcation of potential skin sensitizing chemicals
have included incorporation of oxidizing agents such as
horseradish peroxidase and hydrogen peroxide (HRP/P) as well
as cytochrome P450 enzymes to metabolically activate unreactive
haptens into their more reactive hapten form, a process that
may take place in human skin in vivo (Bergström et al., 2007;
Troutman et al., 2011). By incorporating HRP/P into the DPRA,
83% of 70 chemicals with known sensitizing potential were iden-
tiﬁed accurately as compared with the standard DPRA reported
previously (89%; Troutman et al., 2011). This apparently reduced
accuracy of the HRP/P-added DPRA analysis is misleading,
however, as the initial chemical set used to evaluate the previous
DPRA prediction model did not include pre-/pro-haptens
(Gerberick et al., 2007).
More recent reﬁnements aimed at increasing the robustness of
the DPRA to identify skin sensitizing chemicals include using pH
conditions that more closely mimic human skin pH andmeasure-
ment of concomitant chemical-speciﬁc mass changes indicative
of peptide adduct formation (Dietz et al., 2013). In other work,
the rate constant for reactivity of various test chemicals with
the DPRA peptide was determined to assess whether quanti-
tative kinetic reactivity data generated by measuring cysteine
depletion at multiple test chemical concentrations and at various
incubation times, were correlated with their potency as sensi-
tizers (Roberts and Natsch, 2009; Natsch et al., 2014). However,
drawbacks of this approach are that chemical reactivity varies
markedly between various functional groups and the reaction
rate of test chemicals with the DPRA peptide may not be linearly
related to their in vivo sensitization potency (Roberts and Natsch,
2009).
DPRA: Application to ERS
While cysteine and lysine are the most widely utilized peptides
for the in vitro DPRA, other modiﬁed peptides have been investi-
gated. More recently, the utility of the DPRA for classifying the
sensitizing capacity of several epoxies including novel analogs
of DGEBF and phenyl glycidyl ether (PGE), has been examined
using a synthetic peptide, viz PHCKRM (Pro-His-Cys-Lys-Arg-
Met). The extent of peptide (PHCKRM) depletion by six novel
epoxy analogs and the parent epoxide, PGE, was correlated with
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FIGURE 2 | Schematic diagram summarizing the steps involved
in the conduct of in vitro assays currently available for
assessment of skin sensitization potential. (A) Direct peptide
reactivity assay (DPRA), (B) human cell line activation test (h-CLAT),
(C) myeloid U937 skin sensitization test (MUSST), (D) KeratinoSensTM,
(E) loose-fit coculture-based sensitization assay (LCSA), (F) genomic
allergen rapid detection (GARD), and (G) human T-cell priming assay
(hTCPA).
the sensitizing potency of these epoxies determined using in vivo
LLNA assessment (Niklasson et al., 2009). The strong sensitizer,
PGE produced 88% peptide depletion whereas the weak epoxide
sensitizers, butyl glycidyl ether, and butenyl glycidyl ether pro-
duced 46 and 54% peptide depletion, respectively (Niklasson
et al., 2009). In a DPRA evaluation of DGEBF (containing two
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epoxide groups) and two variants (Variant A and Variant B)
using the same synthetic peptide (PHCKRM), the thiol (cysteine)
binding of DGEBF and its variants appeared to be aﬀected by
the terminal epoxide groups (O’Boyle et al., 2012). Variant A
(DGEBF without terminal epoxide groups) did not react with
free thiols whereas variant B (DGEBF with one terminal epoxide
group) did react with thiol groups albeit to a slightly lesser extent
than the diepoxide DGEBF. Interestingly, the reaction rate for
DGEBF that contains two terminal epoxide groups was slightly
faster than that of variant B. These ﬁndings are aligned with
the sensitizing capacity of DGEBF and its variants determined
using the LLNA and the KeratinoSensTM assay (O’Boyle et al.,
2012).
To date, reports on the applicability of the incorporation of
enzymes into the DPRA, as a means of bioactivation for assess-
ing the skin sensitization potential of epoxy resins, are lacking.
It is known that the enzyme, epoxide hydrolase, catalyzes the
hydrolysis of epoxides to their respective dihydrodiol metabo-
lites which react readily with skin proteins. Conversely, the
enzyme, glutathione-S-transferase catalyzes the detoxiﬁcation of
epoxides by formation of glutathione conjugates (Obach and
Kalgutkar, 2010). Hence, future investigation involving incorpo-
ration of epoxide hydrolase and/or glutathione-S-transferase into
the DPRA for analysis of epoxy resin compounds is warranted,
to more closely mimic possible bioactivation and deactivation
processes within human skin that produce reactive electrophilic
intermediates and detoxiﬁed species, respectively.
Issues relating to the poor aqueous solubility of industrial
compounds that have high octanol/water partition coeﬃcients,
present another obstacle for use of DPRA to assess com-
pounds such as epoxy resins. Although various solvents including
dimethylsulfoxide (DMSO), methanol and acetonitrile have been
used to dissolve lipophilic compounds, only small volumes of
these solutions can be used due to their limited miscibility with
an aqueous solution of the peptide to be depleted. To that extent,
microemulsion systems have potential to improve miscibility
between an organic solution of a lipophilic test compound and
that of an aqueous peptide solution; preliminary data suggest that
this approach is worthy of further investigation (Merckel et al.,
2010).
Unacceptable modulation of the test systems by organic sol-
vents limits the range of solvents that can be used for dissolution
of epoxy resins. For example, organic solvents routinely used in
laboratories inhibit cytochrome P450-mediated metabolic reac-
tions, and may potentially fail to activate the enzyme-dependent
sensitizing chemicals in the test system (Li et al., 2010; Troutman
et al., 2011). DMSO is unsuitable for use in the DPRA as its high
reactivity means that it may react with assay peptides resulting
in false positive results. The use of DMSO in the DPRA would
require an additional costly step of purging the reaction system
with an inert gas such as argon, to prevent oxidation of DMSO
(Niklasson et al., 2009).
In Vitro Assays: Cell-Based Models
Human LCs and dendritic cells (DCs) play key roles in skin sensi-
tization (Coutant et al., 1999). Hence, there has been considerable
research attention on development of in vitro systems that mimic
the roles of LCs and DCs in skin sensitization. Initial in vitro
assays using LCs/DCs were limited due to the scarcity of avail-
able LCs and inter-donor variability of DCs (Yoshida et al., 2003).
These factors were compounded by between-laboratory variabil-
ity in cell isolation and cell culture techniques, which led to assay
reproducibility problems (Yoshida et al., 2003). The inter-donor
variability was circumvented by the use of human myeloid cell
lines, such as KG-1, THP-1, MUTZ-3, and U937 that have the
ability to diﬀerentiate into cells with DC-like characteristics (Hu
et al., 1996; Koss et al., 1996; Yoshida et al., 2003). Several in vitro
model systems using human cell lines to assess the skin sensi-
tizing potential of contact allergens have been developed. These
include the human cell line activation assay (h-CLAT), myeloid
U937 skin sensitization test (MUSST), the KeratinoSensTM test
(Figures 2B–D) and the LuSens which were under ECVAM
evaluation (Ade et al., 2006; Ashikaga et al., 2006; Sakaguchi
et al., 2006; Python et al., 2007; Emter et al., 2010; Bauch et al.,
2012). These methods have been reviewed extensively by others
(Mehling et al., 2012; Vocanson et al., 2013), and hence will not
be covered in this review.
Loose-Fit Coculture-Based Sensitization Assay
(LCSA)
An allergen-sensitive in vitro method that combines two layers
of cells, termed the loose-ﬁt coculture-based sensitization assay
(LCSA), was developed using human primary keratinocytes from
healthy donors, and mobile DC-like cells viz peripheral blood
mononuclear cells (PBMCs; Figure 2E; Schreiner et al., 2008).
As keratinocytes are proposed to have a role in haptenation
via maturation of DCs, this assay has the advantage of being
able to detect prohaptens such as isoeugenol (Schreiner et al.,
2008), that are not detected by many in vitro model systems. In
short, inclusion of keratinocytes in this two-tiered cell-based sys-
tem facilitated metabolic activation of prohaptens into sensitizing
agents akin to that which occurs in the skin in vivo (Wanner et al.,
2010).
Similarly to MUSST and h-CLAT (as depicted in
Figures 2B,C), LCSA quantiﬁes the increase in expression
of the cell surface marker, CD86 (Schreiner et al., 2007).
Additionally, LCSA accuracy and sensitivity for assessing metal
allergens such as nickel and cobalt, was improved by measuring
accumulation of the proinﬂammatory cytokine, interleukin-6
(IL-6) and the chemokine macrophage inﬂammatory protein 1-β
(MIP-1β; Schreiner et al., 2008). In a comparative evaluation of
the in vitro LCSA relative to the in vivo LLNA for assessing the
skin sensitizing potential of a group of textile disperse dyes, both
methods identiﬁed 87.5% of these dyes as having skin sensitizing
potential. Hence, the LCSA is a promising in vitro method for
identifying agents with skin sensitizing potential for use in com-
bination with other non-animal testing methods (Sonnenburg
et al., 2012). However, the current challenges in using the LCSA
include the necessity to obtain keratinocytes and PBMCs from
healthy human donors which makes the method susceptible to
inter-donor variability. Additionally, the complexity and time
required for seeding keratinocytes and PBMCs in this co-culture
assay makes it low throughput and so future innovation is
required to adapt the LCSA to high throughput format.
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Genomic Allergen Rapid Detection (GARD)
Apart from quantiﬁcation of changes in cell surface expression
of molecules of interest, genomic methods may oﬀer an alterna-
tive or complementary in vitro testing paradigm. For example,
genomic allergen rapid detection (GARD) employs the myeloid
cell line, MUTZ-3 that resembles skin DCs with respect to tran-
scriptional proﬁles and the ability to activate speciﬁc T-cell popu-
lations (Figure 2F; Johansson et al., 2013). GARDuses a complete
genome expression array approach to measure expression levels
of 200 transcripts involved in the activation of various signaling
pathways involved in skin sensitization.
Unlike the KeratinoSensTM, MUSST and h-CLAT in vitro
methods that use speciﬁc markers for classifying sensitizers,
GARD utilizes ‘biomarker signatures’ for identifying skin sensi-
tizers, thereby potentially increasing the predictive ability of the
method. An added advantage of GARD is that it can distinguish
respiratory and skin allergens by their unique biomarker signa-
tures (Johansson et al., 2013). Encouragingly, use of GARD to
assess 38 chemicals with known skin sensitization potential in
a preliminary study, showed that the accuracy, sensitivity, and
speciﬁcity of the method was high at 99% (Johansson et al.,
2011).
Recently, Albrekt et al. (2014) stressed that chemical reactiv-
ity properties were key factors for consideration when developing
in vitro screening models of chemical sensitizers. Sensitizing
chemicals were divided into groups based upon their mechanis-
tic reactivity and assessed against various cell-signaling pathways
using the GARD assay. Interestingly, diﬀerent chemical reactivity
groups induced diﬀerential changes in various cell signaling path-
ways, particularly those involved in cell cycling and metabolism.
Potency in modulating these pathways appeared to be correlated
with skin sensitization potential (Albrekt et al., 2014). However,
care is required to avoid over-interpretation of these associations
with respect to potential sensitizer classiﬁcation. More work is
clearly required using larger numbers of chemicals with a broad
range of functional groups of varying reactivity, as well as a range
of concentrations and reaction times. Nevertheless, the GARD
assay can provide invaluable information on the various cell sig-
naling pathways underpinning the sensitization process which is
invaluable in informing further development of in vitro sensiti-
zation test methods. Future research is warranted to assess the
extent to which the epoxide group in ERS will modulate cell-
signaling responses based upon their reactivity domain and/or
their sensitizing potency.
T-cell Activation Model
During skin sensitization, speciﬁc eﬀector and memory T-cells
are activated by DCs triggered by sensitizing agents. While acti-
vation and proliferation of T-cells reﬂect the ultimate step in
inducing sensitization, there are very few assays that address this
aspect of the sensitization process. At present, only the in vivo
LLNA is used widely to evaluate the activation and expansion
of T-cells. More recently, an in vitro assay known as the human
T-cell priming assay (hTCPA) was developed to assess T-cell
responses initiated by contact allergens (Figure 2G; Dietz et al.,
2010; Richter et al., 2013). The hTCPA uses naïve T-cells isolated
from PBMCs of healthy donors that are depleted in CD25+ and
CD45RO+, a T-cell population responsible for regulating hapten-
speciﬁc interferon-γ (IFN-γ)-producing T-cells in lymph nodes
(Vocanson et al., 2013). Themodiﬁed T-cells are co-cultured with
hapten-treated monocyte-derived DCs at two stages, priming and
re-stimulation. After re-stimulation, the increase in T-cell pro-
duction and the cytokines, IFN-γ and TNF-α (tumor necrosis
factor-α), are quantiﬁed using an enzyme-linked immunosorbent
assay (ELISA) and an intracellular cytokine assay (Richter et al.,
2013; Vocanson et al., 2013).
The hTCPA has been used successfully to assess the
skin sensitizing potential of the strong sensitizers, 2,4-
dinitrochlorobenzene (DNCB), 2,4-dinitrobenzenesulfonic
acid (DNBS) 2,4,6-trinitrobezene sulfonic acid (TNBS), and
moderate/weak sensitizers, ﬂuorescein isothiocyanate (FITC),
and α-hexyl cinnamaldehyde (HCA) as well as the non-
sensitizers, methyl salicylate, DMSO, and sodium lauryl sulfate
(SLS; Vocanson et al., 2014). Hence, the hTCPA has potential
as an in vitro method for assessing the sensitizing potential of
contact allergens. However, similar to the LSCA, this method
is time-consuming and fraught with diﬃculty in assay repro-
ducibility due to the scarcity of T-cell donors and inter-donor
variability. More work is warranted to assess the applicability
and generalizability of this cell-based model system using a
larger number and a wider range of chemical compound classes.
For example, the hydrophobic compound, DNCB that reduced
DCs uptake did not stimulate T-cell proliferation (Dietz et al.,
2010). While the use of nanoparticle encapsulation of lipophilic
compounds signiﬁcantly increased the ability of DNCB to stim-
ulate T-cell proliferation and thus increase the assay sensitivity
(Vocanson et al., 2013), inclusion of this additional step adds
another level of complexity and increases the cost of the assay.
Cell-Based Models and ERS
Despite signiﬁcant progress in the development and optimiza-
tion of non-animal testing assays, a major limitation in their
use for accurately identifying the skin sensitizing capacity of test
compounds, is poor water solubility, particularly for aqueous cell-
based assays (McKim et al., 2012). To date, few ERS compounds
have been assessed using cell-based in vitromodel systems. While
the KeratinoSensTM assay has been used successfully to clas-
sify the skin sensitizing potential of DGEBA, DGEBF, and PGE
(Delaine et al., 2011; O’Boyle et al., 2012; Natsch et al., 2013) to
match the LLNA results, the generalizability of other in vitro cell-
based methods reviewed herein is a knowledge gap and remains
to be determined.
Maintaining a suitable balance between the ﬁnal solvent
composition, test compound solubility and deleterious solvent-
related eﬀects within the assay, is pivotal for generating meaning-
ful data on skin sensitization potential. In general, the solvent-
related issues associated with in vitro assays relate to toxic-
ity and/or solvent-mediated modulation of the assay response,
thereby confounding assay readouts resulting in inaccurate
assessment of skin sensitization potential. High solvent concen-
trations in cell-based assays adversely aﬀect cellular integrity,
resulting in cell death (Tapani et al., 1996; Galvao et al., 2014).
Concentration-related toxic eﬀects of the solvent need be evalu-
ated to identify the maximum ‘no eﬀect’ levels for each in vitro
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assay. The balance between acceptable solvent percentage in the
aqueous cell-based test system whilst maintaining solubility of
high molecular weight and low solubility test compounds, par-
ticularly industrial epoxy resins is yet to be adequately addressed.
This issue is arguably themost signiﬁcant obstacle to be overcome
in adapting current in vitro skin sensitization assays to assessment
of epoxy resin hazard risk.
Skin Models
While selection of solvents compatible with in chemico assays
may improve the ability of the DPRA to identify epoxy resins
that have skin sensitizing properties, it is more diﬃcult to attain
a suitable balance between epoxy resin solubility and cell viability
in aqueous culture-based assays. Moreover, future investigation
is required regarding the fact that most test compounds are
applied in solution to in vitro assays which may not necessarily
be reﬂective of the situation in humans where there may be top-
ical application of the compound in the solid state to the skin.
To address this issue, the reconstructed human epidermis (RHE)
has considerable potential. The RHE comprises an acellular der-
mal matrix mimicking the human skin epidermis layer. It has
been used together with cytokines and growth factors to bet-
ter represent the human skin micro-environment (Gibbs et al.,
2007). Preliminary data using the RHE system showed that it was
responsive to known sensitizers (Uchino et al., 2011).
More recently, EpiSensA, an in vitro skin sensitization assay
that utilizes a commercially available RHE has become avail-
able (Saito et al., 2013). In brief, using this skin model system,
skin sensitizing potential of test compounds is assessed based
upon changes in the expression of genes related to the cellu-
lar stress response. Preliminary data from 16 test compounds
were promising (Saito et al., 2013). Despite considerable progress,
the challenge remains for a more complete human skin model
system to become available that has a high degree of accuracy
for correctly identifying and classifying the skin sensitization
potential of novel compounds. This challenge is multi-factorial
encompassing inter-individual diﬀerences at both the cellular
and molecular levels such as genotypic variation, diﬀerences in
epidermal thickness and metabolic activity of the skin, as well
as inter-individual diﬀerences in rates of skin cell diﬀerentia-
tion (Gibbs et al., 2007). Nevertheless, EpiSensA has promise
for improving in vitro assessment of the skin sensitizing prop-
erties of compounds with poor aqueous solubility such as epoxy
resins.
Challenges in Assessing Epoxy Resin
Compounds Using non-Animal Testing
Systems
Apart from use of RHE model systems, the accuracy of in vitro
methods for skin sensitization assessment of industrial chemicals
may be improved by including multiple assay readouts using an
‘assay panel’ approach (Natsch et al., 2009; Jaworska et al., 2011;
Bauch et al., 2012). However, questions on the generalizability of
these in vitromethods to accurately identify chemicals containing
very diﬀerent functional groups, is as yet unclear. In particular,
most in vitro methods were developed and evaluated using small
molecule chemicals that are widely utilized in the manufacture
of cosmetic and toiletry products. This is a signiﬁcant limitation
as it has now been shown that diﬀerent functional groups with
varying chemical reactivity produce diﬀerential engagement of
cell signaling pathways (Albrekt et al., 2014).
For example, a dataset of 145 chemical compounds assessed
using the KeratinoSensTM and MUSST assays, those that were
preferentially lysine-reactive resulted in false negatives (Natsch
et al., 2013). These ﬁndings mirror work by others (Migdal
et al., 2013) whereby chemicals with high reactivity toward
cysteine, and not lysine, activated the nuclear factor erythroid-
derived 2-related factor 2 (Nrf2)-ARE pathway in THP-1 cells,
a well-known toxicity pathway activated by skin sensitizers
(Natsch, 2010) that underpins the design principles of both
the KeratinoSensTM and LuSens tests. ERS compounds such as
DGEBA, DGEBF, and PGE react selectively with thiol groups
(cysteine; O’Boyle et al., 2012; Natsch et al., 2013). Hence, the
KeratinoSensTM and LuSens assays that are based on the afore-
mentioned pathway are worthy of future investigation for their
applicability and reliability to assessment of the skin sensitizing
potential of epoxy resins.
However, it is important to bear in mind that a single stand-
alone method based upon a single mechanistic pathway to assess
novel derivatives of ERS compounds is fraught as the novel
derivatives may produce skin sensitization by a diﬀerent mecha-
nistic pathway. To address this issue, ECVAM recommendations
are that the KeratinoSensTM be used as part of an integrated
assessment approach that may also include the DPRA (ECVAM,
2014). Hence, future research is required to assess the applica-
bility of current in vitro methods to assess the skin sensitizing
potential of a broader range of chemical compounds as a means
to identify the most appropriate in vitro assays and assay readout
ranges, for establishing benchmarks to use for classifying the skin
sensitization potency of novel compound classes.
Another consideration to this discussion is the inherent accu-
racy of the LLNA itself with respect to existing human data.
The LLNA is widely utilized as the benchmark for evaluating
the predictive accuracy of non-animal methods. However, when
compared against the human maximization and patch test, the
accuracy of the LLNA was 72% (Anderson et al., 2011). More
recently, a retrospective comparison of a moderately large dataset
(>100) of test compounds revealed an 82% predictive accuracy
for LLNA when compared with established human data (Urbisch
et al., 2014). In other work, use of an integrated testing strategy-
based on data from ‘2 out of 3 in vitro prediction models’ resulted
in a higher overall accuracy (≥90%) when compared with human
data, as opposed to ≤83% using the LLNA dataset (Bauch et al.,
2012; Urbisch et al., 2014). Factors potentially contributing to the
discordance between human and LLNA data include the diﬀer-
ence in skin penetration rates between the mouse and human,
as well as the application method of the test compounds on the
skin (Anderson et al., 2011; Delaine et al., 2011). The volatility
and cytotoxicity of compounds such as the components of ERS,
could aﬀect potency outcomes given the open nature of substance
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application to the mouse ear in the LLNA in contrast with the
occluded dressing used in human patch tests (Delaine et al.,
2011). Hence, where possible, it is important to compare data
produced by various in vitro skin sensitization tests with human
data where available rather than relying solely on comparisons
with LLNA data.
FIGURE 3 | Schematic overview of mechanisms underpinning
non-animal methods for assessing the sensitizing potential of chemical
compounds. (1) Penetration of haptens through the viable epidermis:
Quantitative Structure–Activity Relationship (QSAR). (2) Activation of
keratinocytes in the epidermal layer by haptens: KeratinoSensTM, LuSens. (3)
Secretion of danger signals from the epidermal compartment due to invasion of
haptens: ROS production, genomic fingerprints, and proteomics biomarkers. (4)
Formation of the hapten–protein complex: DPRA, peroxidase peptide reactivity
assay (PPRA) and QSAR, Allergen-peptide/protein interaction assay (APIA). (5)
Maturation of DCs when migrating from epidermal compartment to auricular
lymph nodes via afferent lymphatics: h-CLAT, MUSST, LCSA. (6) T-cell
proliferation in auricular lymph nodes: hTCPA.
TABLE 3 | In vitro methods used in combination for classifying and predicting skin sensitization potential of novel chemical compounds.
Combination methods Description Accuracy Reference
(a) Peptide reactivity
(b) Cell-based ARE† assay
(c) TIMES-SS‡ computer modelling
(d) Calculated octanol-water partition coefficient
• Scores of 0–4 for each individual test
• A binary system is applied for in silico test results
88% (based on LLNA data)
(116 test substances)
Natsch et al. (2009)
(a) DPRA
(b) LuSens (similar principle with
KeratinoSensTM assay) or KerotinoSensTM
assays
(c) h-CLAT or MUSST
• A sensitizer if DPRA and LuSens yield negative
results and MUSST is positive
• If contradictory results between DPRA and
LuSens, or h-CLAT, then weight of evidence
approach is used
94% (based on human data)
83% (based on LLNA data)
(54 test substances)
Bauch et al. (2012)
Bayesian network Integrated Testing Strategy
(a) TIMES§
(b) DPRA
(c) ARE luciferase activity
(d) MUSST
• Adaptive testing strategy where the choice and
sequence of tests performed are based on
available information
• Reduces uncertainty of the sensitizing capacity of
a test substance before proceeding to the
experiment.
– Jaworska et al. (2011)
†ARE, antioxidant response element.
‡TIMES-SS, tissue metabolism simulator for skin sensitization.
§ TIMES, tissue metabolism simulator.
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Integrating Non-Animal Assay
Readouts: Classifying Potential Skin
Sensitizers
The OECD has proposed that the hazard classifying system for
chemicals should consider the potential severity of allergic man-
ifestations from human and animal-based epidemiological data
[Organisation for Economic Co-operation and Development
(OECD), 1998]. A strong sensitizer is deﬁned as a compound
that has a high occurrence of sensitization within an exposed
population whereas low to moderate sensitizers produce a low
or moderate frequency or severity of sensitization [Organisation
for Economic Co-operation andDevelopment (OECD), 1998]. At
present, this chemical classiﬁcation system is based solely on the
‘gold standard’ LLNA which assesses the potency of skin sensitiz-
ers based on the extent to which they induce T-cell proliferation
in the auricular lymph nodes of mice (Kimber et al., 2002b).
Current and future research aimed at gaining a deeper under-
standing of the various cellular and immunological mechanisms
and their interplay that contribute to the extent of sensitiza-
tion evoked, is essential. Such new knowledge will be invaluable
for informing future research aimed at optimization of in vitro
methods for hazard identiﬁcation of industrial chemicals, partic-
ularly ERS, as well as enable quantitative risk assessments to be
performed (Kimber et al., 2011).
The available non-animal testing methods for assessing the
various stages of ACD are summarized in Figure 3. This
schematic diagram clearly shows that single testing methods are
unable to evaluate potential cross-talk between the various phases
of the skin sensitization process. Thus, a single in vitro test repre-
sentative of a single event in the human skin response to contact
allergens cannot adequately capture the complexity of the human
response to a contact allergen, thereby potentially leading to gen-
eration of false negative results (Aeby et al., 2010). Thus, a panel
of complementary non-animal tests that together mimic the com-
plexity inherent in in vivo test methods (e.g., LLNA, human patch
test), has considerable potential utility as a screening tool for
more accurately classifying novel compounds as extreme, strong,
moderate or weak sensitizers.
An integrated hazard classiﬁcation scheme involving assess-
ment of multiple steps in the skin sensitization process, including
bioavailability, structural alerts, formation of hapten–protein
conjugates, DC maturation, and T-cell proliferation, has been
proposed (Kimber et al., 2003; Jowsey et al., 2006). Using this
approach, greater weight is given to in vitro tests that produce
quantitative data. An index of sensitizing potency is calculated
based upon the product of values obtained from each test repre-
senting a key step in the skin sensitization process, for compari-
son of skin sensitization potency with the corresponding mouse
LLNA data (Kimber et al., 2003; Jowsey et al., 2006). Various non-
animal test combinations proposed for identifying potential skin
sensitizers are summarized in Table 3.
Conclusion
A strategy encompassing the integration of readouts from mul-
tiple in vitro tests as a means to improve the accuracy for
identiﬁcation of novel compounds that are contact allergens
has merit. However, implementation of such a strategy requires
extensive validation and assessment of its generalizability for
multiple chemical classes before gaining widespread acceptance.
Additionally, use of an integrated panel of in vitro methods
to screen large numbers of industrial chemicals is likely to be
unattractive from a cost and time perspective and so develop-
ment of a hierarchy of individual high throughput in vitro tests
is needed.
At present, single in vitro assays in high throughput format
enable large numbers of compounds to be screened in a short
time frame. However, the choice of in vitromethod for screening
purposes, either as part of an integrated or hierarchical strategy,
should be informed by knowledge of the chemical class/domain.
In conclusion, the choice of in vitro methods for inclusion in a
panel for assessing skin sensitization potential will be the best
balance between predictive power of the selected tests relative
to the time and cost of generating the data and its value to the
organization that requires the data.
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